1. Liyanage KE, Burnett JR, Hooper AJ, van Bockxmeer FM. Familial hypercholesterolemia: epidemiology, Neolithic origins and modern geographic distribution. Crit Rev Clin Lab Sci 2011; 48(1): 1-18.
2. Bell DA, Hooper AJ, Watts GF, Burnett JR. Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia. Vasc Health Risk Manag 2012; 8: 651-659.
3. Müller C. Xanthomata, Hypercholesterolemia, Angina Pectoris. Acta Medica Scandinavica 1938; 95(S89): 75-84.
4. Khachadurian AK. The inheritance of essential familial hypercholesterolemia.
Am J Med 1964; 37: 402-407.
5. Brown MS, Kovanen PT, Goldstein JL. Regulation of plasma cholesterol by lipoprotein receptors. Science 1981; 212(4495): 628-635.
6. Goldstein JL, Brown MS. The LDL receptor. Arterioscler Thromb Vasc Biol 2009;
29(4): 431-438.
7. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232(4746): 34-47.
8. Seftel HC, Baker SG, Sandler MP, et al. A host of hypercholesterolaemic homozygotes in South Africa. Br Med J 1980; 281(6241): 633-636.
9. Fahed AC, Safa RM, Haddad FF, et al. Homozygous familial hypercholesterolemia in Lebanon: a genotype/phenotype correlation. Mol Genet Metab 2011; 102(2): 181-188.
10. Moorjani S, Roy M, Gagne C, et al. Homozygous familial hypercholesterolemia among French Canadians in Quebec Province. Arteriosclerosis 1989; 9(2):
211-216.
11. Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. BMJ 1991;
303(6807): 893-896.
12. Skopelitou K, Dhavala P, Papageorgiou AC, Labrou NE. A glutathione transferase from Agrobacterium tumefaciens reveals a novel class of bacterial GST superfamily. PLoS One 2012; 7(4): e34263.
13. Williams RR, Hunt SC, Schumacher MC, et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics.
The American journal of cardiology 1993; 72(2): 171-176.
14. Raal FJ, Santos RD. Homozygous familial hypercholesterolemia: Current perspectives on diagnosis and treatment. Atherosclerosis 2012; 223(2): 262-268.
15. Raal FJ, Pilcher GJ, Panz VR, et al. Reduction in mortality in subjects with
homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation 2011; 124(20): 2202-2207.
16. Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008; 358(14): 1431-1443.
17. Robinson JG. Management of familial hypercholesterolemia: a review of the recommendations from the national lipid association expert panel on familial hypercholesterolemia. J Manag Care Pharm 2013; 19(2): 139-149.
18. Robinson JG, Goldberg AC. Treatment of adults with familial hypercholesterolemia and evidence for treatment: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011; 5(3 Suppl): S18-29.
19. Goldberg AC, Hopkins PN, Toth PP, et al. Familial hypercholesterolemia:
screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011; 5(3): 133-140.
20. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106(25):
3143-3421.
21. Minhas R, Humphries SE, Qureshi N, Neil HA. Controversies in familial hypercholesterolaemia: recommendations of the NICE Guideline Development Group for the identification and management of familial hypercholesterolaemia.
Heart 2009; 95(7): 584-587; discussion 587-591.
22. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). The American journal of cardiology 1998; 81(5): 582-587.
23. Hamilton-Craig I, Kostner K, Colquhoun D, Woodhouse S. Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia. Vasc Health Risk Manag 2010; 6: 1023-1037.
24. Avellone G, Di Garbo V, Guarnotta V, et al. Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia.
Int Angiol 2010; 29(6): 514-524.
25. Gagne C, Gaudet D, Bruckert E. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002; 105(21): 2469-2475.
26. Robinson JG, Davidson MH. Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction. Expert Rev Cardiovasc Ther
2006; 4(4): 461-476.
27. Thompsen J, Thompson PD. A systematic review of LDL apheresis in the treatment of cardiovascular disease. Atherosclerosis 2006; 189(1): 31-38.
28. Thompson GR. Lipoprotein apheresis. Curr Opin Lipidol 2010; 21(6): 487-491.
29. Thompson GR, Catapano A, Saheb S, et al. Severe hypercholesterolaemia:
therapeutic goals and eligibility criteria for LDL apheresis in Europe. Curr Opin Lipidol 2010; 21(6): 492-498.
30. Moini M, Mistry P, Schilsky ML. Liver transplantation for inherited metabolic disorders of the liver. Curr Opin Organ Transplant 2010; 15(3): 269-276.
31. US FDA. Drugs@FDA: FDA Approved Drug Products. Lomitapide. Available from:
http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Sear ch.DrugDetails [Accessed March 13, 2014].
32. Dixon DL, Sisson EM, Butler M, Higbea A, Muoio B, Turner B. Lomitapide and Mipomersen: Novel Lipid-Lowering Agents for the Management of Familial Hypercholesterolemia. J Cardiovasc Nurs 2013.
33. Rader DJ, Kastelein JJ. Lomitapide and Mipomersen: Two First-in-Class Drugs for Reducing Low-Density Lipoprotein Cholesterol in Patients With Homozygous Familial Hypercholesterolemia. Circulation 2014; 129(9): 1022-1032.
34. 「 適 用 罕 見 疾 病 防 治 及 藥 物 法 之 藥 物 品 項 」 修 正 草 案 . Available from:
http://www.fda.gov.tw/TC/newsContent.aspx?id=10660&chk=37cbddea-dec5-49 df-9bf1-c3c945a93561¶m=pn%3D6%26cid%3D3%26cchk%3D46552e96-8 10a-42c3-83e1-bd5e42344633#.UyAbPCwVF9B [Accessed March 12, 2014].
35. WHO Collaborating Centre for Drug Statistics Methodology. Available from:
http://www.whocc.no/atc_ddd_index/ [Accessed March 12, 2014].
36. 衛生福利部食品藥物管理署. 西藥、醫療器材、化粧品許可證查詢. Available from:
http://www.fda.gov.tw/MLMS/(S(ejyfg32p1fuxjz55ywrqbl45))/H0001D.aspx?Ty pe=Lic&LicId=02024058 [Accessed March 12, 2014].
37. 全 民 健 康 保 險 降 血 脂 藥 物 給 付 規 定 ： 第 2 節 心 臟 血 管 及 腎 臟 藥 物 Cardiovascular-renal drugs，2.6.降血脂藥物 Drugs used for dyslipidemia. 行 政 院 衛 生 署 中 央 健 康 保 險 局 . Available from http://www.nhi.gov.tw/resource/Webdata/22868_1_全民健康保險藥品給付規定 -102 年版(整份帶走).doc Accessed 20130416.
38. NICE clinical guidelines. Identification and management of familial hypercholesterolaemia. CG71. 2008 August. Available from:
http://publications.nice.org.uk/identification-and-management-of-familial-hyperc holesterolaemia-cg71 [Accessed March 12, 2014].
39. Cuchel M, Meagher EA, du Toit Theron H, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 2013; 381(9860): 40-46.
40. Scottish Medicines Consortium. Lomitapide (Lojuxta® ) for adjunct to a low-fat diet and other lipid-lowering medicinal products with or without low density lipoprotein (LDL) apheresis in adult patients with homozygous familial hypercholesterolaemia (HoFH). No. (956/14). Scottish Medicines Consortium.
http://www.scottishmedicines.org.uk/SMC_Advice/Advice/956_14_lomitapide_L ojuxta/lomitapide_Lojuxta. Published 2014. Accessed February 27, 2014.
41. 郭惠珍. 疾病資料庫：同合子家族性高膽固醇血症(Homozygous familial hypercholestrolemia). 疾病資料庫.
http://www.genes-at-taiwan.com.tw/genehelp/database/disease/Homozygous_fam ilial_hypercholestrolemia.htm. Published 2006. Accessed March 3, 2014.
42. Kolansky DM, Cuchel M, Clark BJ, et al. Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia. The American journal of cardiology 2008; 102(11):
1438-1443.
43. Rader DJ, Cohen J, Hobbs HH. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. The Journal of clinical investigation 2003; 111(12):
1795-1803.
44. 郝雪卿. 疾病資料庫：台中榮總應用血漿分離術 治療高膽固醇血症. 疾病資 料庫.
http://www.genes-at-taiwan.com.tw/genehelp/database/disease/Homozygous_fam ilial_hypercholestrolemia_news_3.htm. Published 2004. Accessed March 3, 2014.
45. 財團法人醫藥品查驗中心醫藥科技評估組. 全民健康保險藥事小組會議參考 資料：Kynamro Inj (Antisense inhibitor of apolipoprotein B-100) 醫療科技評估 報告. 衛生福利部中央健康保險署. Published 2013. Accessed February 28, 2014.
46. ATC/DDD Index 2013. WHO Collaborating Centre for Drug Statistics Methodology. http://www.whocc.no/atc_ddd_index/. Published 2014. Accessed February 27, 2014.
47. Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 375(9719): 998-1006.
附錄
附 錄 表 一 、 Effects of Lomitapide and Mipomersen on Atherogenic Lipoprotein Parameters in hoFH (Phase 3 Studies) [33]
Lomitapide*
(n=29)
Mipomersen†
(n=34) 總膽固醇
Baseline, mg/dL 428 502
Mean change, % −36 −21
LDL cholesterol
Baseline, mg/dL 336 440
End point, mg/dL 190 324
Mean change, % -40 −25
Non-HDL cholesterol
Baseline, mg/dL 386 463
Mean change, % -40 -25
ApoB
Baseline, mg/dL 260 280
Mean change, % -39 -27
Lipoprotein (a)
Baseline, mg/dL 66 60
Change, % -13 -32
*Based on values at 26 weeks in all 29 subjects in an intention-to-treat analysis with the last observation carried forward. Change from baseline was statistically significant for all parameters. (single-arm，開放標籤之第3期臨床試驗)[39]
†Based on values obtained at the visit closest to 14 days after the last dose of study treatment.
Change from baseline was statistically significant for all parameters. (隨機分派、雙盲、安慰 劑對照之第3期臨床試驗)[40]
附錄表二 經濟評估文獻搜尋記錄
資料庫 查詢日期 關鍵字 篇數
PubMed
1950-2014 20140303 #1 lomitapide OR Juxtapid OR Lojuxta
#2((((economic)) OR (cost))) OR (((cost-benefit analysis)) OR ((treatment outcome) AND ec))
#3 #1 AND #2
6
EMBASE
1980-2014 20140303 #1 lomitapide OR Juxtapid OR Lojuxta
#2((((economic)) OR (cost))) OR (((cost-benefit analysis)) OR ((treatment outcome) AND ec))
#3 #1 AND #2
filter publication type as ‘article’ or ‘article in press’
4
Cochrane Library 1800-2014
20140303 lomitapide OR Juxtapid OR Lojuxta Limited to ‘economic evaluation’
0
NHS Center for Reviews and
Dissemination
20140303 #1 lomitapide OR Juxtapid OR Lojuxta limited to ‘NHS EED’
0
Chinese Electronic Periodical Services AND Chinese Electronic Theses &
Dissertations Service
20140303 #1 lomitapide CEPS1
CETD0